Manel Kraiem
Chief Development Officer Skymab Biotherapeutics
Dr. Manel Kraiem Merabet is Chief Development Officer at Skymab, with over 11 years of experience in translational and clinical oncology research. Formerly a Scientific leader at Innate Pharma, she led ADC programs from target selection, lead optimization to IND and is regarded as an ADC expert. She is the patent inventor of several ADCs, including ADCs anti-GPCRs, IPH45, currently under clinical development. Dr. Merabet has served as Chair of multiple sessions, including the Linker Summit in Boston, the ADC Summit in Amsterdam and 4th Annual GPCRs-Targeted Drug Discovery Summit . She holds a PharmD, a PhD in Oncology and Immunology, a European radiopharmacy–radiobiology degree from CEA Saclay, and a Master’s in Organic Chemistry from Saint Jerome University. She collaborates with leading biotech and pharma partners and has been recognized as an invited expert speaker at major ADC and oncology conferences, including the World ADC Summit.
Seminars
- Developing predictive biomarkers to identify oncology patients most likely to respond to GPCR-targeted ADCs or radio-conjugates, enabling precision therapy selection
- Leveraging human-derived tumour models (patient-derived xenografts, resistant models) to translate GPCR biology into clinically relevant drug responses
- Implementing advanced target engagement assays to confirm ADC binding, internalisation, and payload release within the tumour microenvironment
